168 related articles for article (PubMed ID: 15899728)
1. Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy.
Chrischilles EA; Klepser DG; Brooks JM; Voelker MD; Chen-Hardee SS; Scott SD; Link BK; Delgado DJ
Pharmacotherapy; 2005 May; 25(5):668-75. PubMed ID: 15899728
[TBL] [Abstract][Full Text] [Related]
2. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States).
Chen-Hardee S; Chrischilles EA; Voelker MD; Brooks JM; Scott S; Link BK; Delgado D
Cancer Causes Control; 2006 Jun; 17(5):647-54. PubMed ID: 16633911
[TBL] [Abstract][Full Text] [Related]
3. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.
Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
Value Health; 2011; 14(2):253-62. PubMed ID: 21402294
[TBL] [Abstract][Full Text] [Related]
5. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
6. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma.
Rubino C; Laplanche A; Patte C; Michon J
J Natl Cancer Inst; 1998 May; 90(10):750-5. PubMed ID: 9605644
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma.
Souêtre E; Qing W
Pharmacoeconomics; 1994; 6 Suppl 2():36-43. PubMed ID: 10172484
[TBL] [Abstract][Full Text] [Related]
8. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
Weycker D; Barron R; Kartashov A; Legg J; Lyman GH
J Oncol Pharm Pract; 2014 Jun; 20(3):190-8. PubMed ID: 23824496
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
[TBL] [Abstract][Full Text] [Related]
10. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma.
Chrischilles E; Delgado DJ; Stolshek BS; Lawless G; Fridman M; Carter WB
Cancer Control; 2002; 9(3):203-11. PubMed ID: 12060818
[TBL] [Abstract][Full Text] [Related]
11. Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.
Tai E; Guy GP; Dunbar A; Richardson LC
J Oncol Pract; 2017 Jun; 13(6):e552-e561. PubMed ID: 28437150
[TBL] [Abstract][Full Text] [Related]
12. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
13. Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice.
Weycker D; Danel A; Marciniak A; Bendall K; Lipsitz M; Pettengell R
BMC Cancer; 2012 Aug; 12():362. PubMed ID: 22913768
[TBL] [Abstract][Full Text] [Related]
14. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.
Bennett CL; Armitage JL; Armitage GO; Vose JM; Bierman PJ; Armitage JO; Anderson JR
J Clin Oncol; 1995 Apr; 13(4):969-73. PubMed ID: 7707125
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Cost Comparison Evaluation of Inpatient Versus Outpatient Administration of EPOCH-Containing Regimens in Non-Hodgkin Lymphoma.
Evans SS; Gandhi AS; Clemmons AB; DeRemer DL
J Pharm Pract; 2017 Aug; 30(4):400-405. PubMed ID: 27432462
[TBL] [Abstract][Full Text] [Related]
16. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
[TBL] [Abstract][Full Text] [Related]
17. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy.
Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
J Am Geriatr Soc; 2010 Oct; 58(10):1885-95. PubMed ID: 20840455
[TBL] [Abstract][Full Text] [Related]
19. Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma.
Zelenetz AD
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):21-6. PubMed ID: 14682115
[TBL] [Abstract][Full Text] [Related]
20. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Sutheesophon J; Sutcharitchan P; Swasdikul D
Leuk Lymphoma; 2000 Apr; 37(3-4):351-60. PubMed ID: 10752986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
